UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): September 17,
2008
Immunomedics,
Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-12104
|
61-1009366
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
300
American Road, Morris Plains, New Jersey
|
07950
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(973)
605-8200
|
|
(Registrant's
telephone number,
including
area code)
|
|
|
|
Not applicable
|
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
[
] Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425).
[
] Soliciting material pursuant to
Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
[
] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).
[
] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)).
Item
7.01 Regulation FD Disclosure.
On
September 17, 2008, Immunomedics, Inc., a Delaware corporation (the “Company”),
provided a detailed review and update of the Company’s clinical pipeline,
including plans for future clinical and research developments at the Company’s
Research and Development (“R&D”) Day held at the Waldorf Astoria Hotel in
New York City. The full transcript of the Company’s
presentations, including question and answer sessions is attached to this
current report on Form 8-K as Exhibit 99.1.*
On
September 17, 2008, the Company issued a press release announcing highlights
from its R&D Day. The full text of the press release is attached
to this current report on Form 8-K as Exhibit 99.2.
Item
9.01. Financial Statements and
Exhibits.
(d) Exhibits.
|
Exhibit
No.
|
|
Description
|
|
99.1
|
|
Transcript
of the R&D Day presentations including question and answer
sessions.
|
|
|
|
|
|
99.2
|
|
Press
Release of Immunomedics, Inc. dated September 17,
2008.
|
* The
information furnished pursuant to Item 7.01 of this Form 8-K including Exhibit
99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
IMMUNOMEDICS,
INC.
By:
/s/ Cynthia L.
Sullivan
Name:Cynthia
L. Sullivan
Title:President
and Chief Executive Officer
Date: September
22, 2008